Case Report: Trastuzumab deruxtecan in human epidermal growth factor receptor 2-mutated lung cancer with continuous renal replacement therapy

T-DXd treatment in this CRRT-dependent patient with HER2-mutant lung cancer achieved disease control with manageable toxicity. While demonstrating potential clinical utility, the short survival period warrants cautious interpretation. Further validation is needed to establish its role in this population.